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ABSTRACT
Transmembrane mucins (TMs) are restricted to the apical surface of normal 
epithelia. In cancer, TMs not only are over-expressed, but also lose polarized 
distribution. MUC16/CA125 is a high molecular weight TM carrying the CA125 
epitope, a well-known molecular marker for human cancers. MUC16 mRNA and 
protein expression was mildly stimulated by low concentrations of TNFα (2.5 ng/
ml) or IFNγ (20 IU/ml) when used alone; however, combined treatment with both 
cytokines resulted in a moderate (3-fold or less) to large (> 10-fold) stimulation of 
MUC16 mRNA and protein expression in a variety of cancer cell types indicating that 
this may be a general response. Human cancer tissue microarray analysis indicated 
that MUC16 expression directly correlates with TNFα and IFNγ staining intensities in 
certain cancers. We show that NFκB is an important mediator of cytokine stimulation 
of MUC16 since siRNA-mediated knockdown of NFκB/p65 greatly reduced cytokine 
responsiveness. Finally, we demonstrate that the 250 bp proximal promoter region 
of MUC16 contains an NFκB binding site that accounts for a large portion of the 
TNFα response. Developing methods to manipulate MUC16 expression could provide 
new approaches to treating cancers whose growth or metastasis is characterized by 
elevated levels of TMs, including MUC16.
INTRODUCTION
Mucins are high molecular weight glycoproteins that 
are normally found on apical surfaces of epithelial organs 
such as trachea, stomach, and reproductive organs [1], 
where they serve various functions including protection 
against pathogenic infections, hydration and cellular 
signaling [2]. To date, 20 mucin genes have been identified 
and are classified based on the presence of large, heavily 
O-glycosylated, tandem repeat motifs [3]. Mucins can be 
membrane bound or secreted depending on the presence 
of a membrane spanning region [2]. Of the cell surface 
bound mucins, MUC1, MUC4 and MUC16 are the best 
characterized [4].
Mucins are a class of molecules that aid in mucosal 
defense by providing a large physical cell surface 
barrier to pathogens and tissue-degrading enzymes [1]. 
Mucins normally function to protect and lubricate the 
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epithelium, but are overexpressed in various cancers [5], 
are frequently used as diagnostic markers [6, 7], and are 
being considered as therapeutic targets [8]. Alterations 
in transmembrane mucin expression or glycosylation 
promote the development of cancer and stimulate cell 
growth, differentiation and invasion [9, 10]. MUC16 (also 
known as the serum tumor marker, CA 125) is the largest 
transmembrane mucin being 2–5 MDa including O-linked 
and N-linked glycosylation. The polypeptide backbone of 
MUC16 contains 22,000 amino acids [11, 12], including 
an N-terminal tandem repeat region composed of 18–60 
repeats of 156 amino acids each, and a C-terminal region 
with a short cytoplasmic tail [4, 12]. Intact MUC16 is the 
largest membrane glycoprotein known, towering over 
even other large cell surface mucins like MUC1 and 
MUC4.  As such, it likely represents the initial point of 
contact with other cells and matrices.  MUC16 is believed 
to play important roles not only in normal contexts such 
as reproduction, but also in pathological states including 
cancer and mucosal infections [13–15]. MUC16 has been 
used as a tumor marker for over thirty years due to its 
overexpression in ovarian and other cancers, yet little is 
known about its regulation. The importance of MUC16 in 
the diagnosis, progression and therapy of ovarian cancer, 
and its overexpression in other cancers, demands a need 
for research on the regulation of this mucin.
Eighty to 90 percent of all cancers originate 
in epithelial tissue. Membrane bound mucins are 
overexpressed in many of these cancers as well as in 
other pathological conditions [2]. The causes of mucin 
overexpression are not always clear, but include gene 
duplication [16], and mucin gene responsiveness to factors 
in the tumor microenvironment [17].  High levels of 
transmembrane mucins on tumor cells protect these cells 
from attack by the host immune system as well as from the 
actions of cytotoxic drugs [17].
The regulation of expression of certain mucins, 
particularly MUC1, has been well studied and is markedly 
stimulated by cytokines [18–21]. Inflammatory events 
trigger cytokine release by immune cells, which invade 
tumor-associated stroma. Inflammation and cytokine 
production are one of the proposed “hallmarks of cancer” 
implicating their significant role in tumorigenesis [22]. 
Furthermore, it has been shown that NFκB directly binds 
to the MUC1 promoter to activate gene transcription 
(12). NFκB generally plays a key role as a mediator 
of inflammatory responses, and also has been found to 
play a crucial role in many steps of cancer initiation and 
progression [23]. In spite of the existing detailed information 
on the molecular regulation of MUC1, little is known about 
regulation of MUC16 gene expression [24, 25].
At least 20% of all cancers are associated with 
chronic inflammation, typified by a cytokine-rich 
environment [26]. This inflammation is most often 
assessed by histological detection of tumor-associated 
or infiltrating, cytokine-producing immune cells. Even 
cancers that do not develop from chronic inflammation 
often contain high levels of cytokines [26]. Macrophages 
from tumors secrete inflammatory cytokines including 
TNFα and IFNγ. TNFα has a tumor-promoting role (19), 
and TNFα expression generally increases with tumor stage 
(20). Also, high plasma levels of TNFα correlate with 
higher tumor stage (21). On the other hand, IFNγ has dual 
roles with both pro-inflammatory and anti-inflammatory 
properties [27]. Both cytokines have significant 
physiological importance in regulating immune responses 
and inflammation.  In this study, we link the expression of 
MUC16 to stimulation by TNFα and IFNγ through NFκB 
in cell culture and in pathological specimens. 
RESULTS
Basal MUC16 mRNA levels in various cell types 
differ among normal epithelial cells derived from 
breast, ovarian and endometrial cancers
 Initially, we determined basal MUC16 mRNA 
levels in a series of epithelial cells derived from female 
reproductive tissues: IOSE 261F (Table 1 and Figure 1) 
(a normal ovarian epithelial cell type), SKOv3-ip 
(Table 1 and Figure 1), and OVCAR-3 (Table 1 and 
Figure 1), moderately and poorly differentiated ovarian 
cancer cells, respectively, which displayed moderate 
(SKOv3-ip) and very high (OVCAR-3) basal levels of 
MUC16 mRNA; RL95-2 and HEC50, moderately and 
poorly differentiated cells, respectively, derived from 
endometrial adenocarcinomas with moderate basal levels 
of MUC16 (Table 1 and Figure 1); and MCF-7 (breast 
cancer), which displayed very low basal levels of MUC16 
(Table 1 and Figure 1).
TNFα and IFNγ stimulate MUC16 mRNA 
levels in MCF-7 breast cancer cells in a dose-
dependent manner
Pro-inflammatory cytokines stimulate expression 
of MUC1 and MUC4 in other contexts [20], but little 
is known about MUC16 responsiveness in this regard. 
Initially, we determined the dose responsiveness of 
MUC16 mRNA expression to either TNFα or IFNγ in 
MCF-7 cells, which contained the lowest basal levels of 
MUC16 (Figure 1). TNFα was added at concentrations 
ranging from 0.25 ng/ml to 25 ng/ml for 48 h. IFNγ was 
added at concentrations of 2 IU to 200 IU for 48 h. In 
many experiments with MCF-7 cells, but not with other 
cells tested, extremely robust stimulation by cytokines 
was observed (> 50 fold); however, in other experiments 
stimulation was as low as 8-fold (Figure 4).  Decreased 
responsiveness correlated to passage number and reflected 
a higher basal level of MUC16 expression with increasing 
passages. The lowest concentrations of either cytokine that 
demonstrated a significant stimulation of MUC16 mRNA 
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levels were 2.5 ng/ml of TNFα and 20 IU/ml of IFNγ 
(Figure 2A and 2B).  Therefore, these concentrations were 
used in subsequent experiments to determine the potential 
synergy between these cytokines in stimulating MUC16 
expression.
Treatment with TNFα and IFNγ stimulated 
MUC16 mRNA levels in multiple cell types
The ability of low concentrations of TNFα (2.5 
ng/ml) and IFNγ (20 IU) to stimulate MUC16 mRNA 
expression was assessed in multiple cell types. Cells 
were treated for 48 h with either a vehicle control, 
or low cytokine doses individually or in combination 
(Figure 3A–3F).  Values obtained for vehicle controls 
in each case were set to 1 for comparison. Treatments 
with the individual cytokines only modestly stimulated 
MUC16 gene expression (2–3-fold) in any cell context; 
however, combined cytokine treatment provided 
significantly higher stimulation in 5 of 6 cell types. 
The sole exception was OVCAR-3 cells, which display 
extremely high basal levels of MUC16 mRNA (Figure 1). 
Higher cytokine concentrations in combination did not 
further stimulate MUC16 expression in any context 
(data not shown).  Therefore, the stimulation observed 
with the combined cytokine treatments appeared to be 
maximal in each case. The strongest stimulations were 
observed with cells displaying the lowest basal MUC16 
levels, namely IOSE 261F, SKOv3-ip and MCF-7 
(Figure 3A, 3B and 3F).  Modest, predominantly 
TNFα-dependent, stimulation was observed in the two 
uterine adenocarcinoma cell types, HEC50 and RL95-2 
(Figure 3D and 3E), which displayed intermediate basal 
levels of MUC16.
MUC16 protein expression and shedding were 
stimulated in response to treatment with a 
combination of TNFα and IFNγ
Because MCF-7 cells displayed the most robust 
response to cytokine treatment, they were used to perform 
time course studies for MUC16 (CA125) protein and 
mRNA accumulation. MUC16 mRNA (Figure 4A) and 
cell-associated protein (Figure 4B) levels were essentially 
maximal within 6 days of cytokine exposure while media 
levels continued to accumulate throughout the 12 day 
time course (Figure 4C). It also was found that for MCF-
7 cells about 90% of the MUC16 protein produced was 
ultimately found in the media by 12 days of treatment 
(Figure 4C). Consequently, the cytokine stimulation 
of MUC16 mRNA expression was also reflected at the 
level of MUC16 protein expression. We used six days of 
treatment to examine the actions of individual cytokines 
on MUC16 protein expression. A small increase in 
MUC16 stimulation in the cell-associated fraction 
resulted from treatment with IFNγ alone (*p < 0.05). 
Nonetheless, much greater stimulation was observed 
with TNFα or TNFα plus IFNγ in the media and total 
fractions indicating that TNFα was a strong driver of 
MUC16 production (***p < 0.001 vehicle vs TNFα + 
IFNγ) (Figure 5A). 
The effect of cytokine treatment on cell surface 
MUC16 was investigated further in MCF-7 cells by 
immunostaining (Figure 5B panels a through l). The 
promotion of MUC16 expression was a consistent 
response in 5 of the 6 cell types tested.
MUC16, TNFα and IFNγ are coexpressed in 
malignant uterine neoplasms
The in vivo association of cytokine expression with 
that of MUC16 was assessed with immunohistochemical 
staining of a multi-tumor human tissue microarrays. 
Serial sections of a human cancer tissue array were 
stained simultaneously using anti-MUC16 or anti-TNFα 
or anti-IFNγ antibody. The array included various cancers 
including ovary, endometrium and breast, which were the 
focus of this study (Supplementary Table 1). The purpose 
of these studies was to determine if relative MUC16 
expression correlated with TNFα or IFNγ expression, 
independently of tumor stage or grade. Samples were 
classified according to staining intensities, which 
represents protein expression. The array staining generally 
revealed that strong cytokine expression was associated 
with elevated MUC16 expression in many cancers. In 
cancers such as ovarian (Figure 6A and 6C) and breast 
(Figure 6B and 6D), there was a direct correlation 
between the staining intensity for both cytokines and 
MUC16. The correlation for endometrial cancer was not 
as clear (graph not shown).
Table 1: Cell types used in the current study
Cell line Tissue source Type Level of differentiation References
IOSE 261F Ovary-surface epithelium Normal Well Leung, E.H., et al., 2001 [48]
SKOv3-ip Ovary: ascites Adenocarcinoma Moderate Hua, W., et al., 1995 [49]
OVCAR-3 Ovary: ascites Adenocarcinoma Poor Hamilton, T.C., et al., 1983 [50]
RL95-2 Uterus: endometrium Adenocarcinoma Moderate Way, D.L., et al., 1983 [51]
HEC-50 Uterus: endometrium Adenocarcinoma Poor Kassan, S., et al., 1989 [52]
MCF-7 Breast: mammary gland Adenocarcinoma Moderate Soule, H.D., et al.,1973 [53]
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MUC16 mRNA responses to cytokines are 
attenuated when NFκB/p65 is knocked down by 
siRNA
Given the particularly strong actions of TNFα on 
MUC16 expression, we sought to determine if the key 
downstream transcription factor, NFκB, mediated this 
response. To accomplish this, NFκB/p65 was knocked 
down via siRNA in two cell types displaying the strongest 
MUC16 mRNA elevation in response to cytokines, 
namely MCF7 and SKOv3-ip. NFκB/p65 knockdown 
reduced target mRNA and protein levels by 60–80% of the 
control (Figure 7A and 7B and Supplementary Figure 1). 
Cytokine stimulated MUC16 mRNA levels were 
significantly (p < 0.001) decreased when NFκB/p65 was 
knocked down in both cell types (Figure 7C and 7D). This 
also was the case even when TNFα or IFNγ were added 
individually (Supplementary Figure 2). Collectively, these 
studies demonstrate that NFκB is an important mediator 
for both TNFα and IFNγ responsiveness. While was not 
further elevated MUC16 expression in OVCAR-3 cells in 
response to cytokines (Figure 3), we used siRNA-mediated 
knockdown to determine if NFκB mediated high level 
MUC16 expression in this cell context. Though we again 
Figure 2: TNFα and IFNγ stimulate MUC16 mRNA levels in a dose dependent manner. MCF-7 cells were treated with the 
indicated concentrations of TNFα (panel A) or IFNγ (panel B) for 48 h, RNA extracted and the levels of MUC16 mRNA relative to those 
of ACTB were determined by qRT-PCR as described in Materials and Methods. The boxes indicate the lowest concentrations of either 
cytokine that demonstrated a significant stimulation of MUC16 mRNA levels and were used in subsequent experiments to determine the 
potential synergy of action between these cytokines.  Values for the vehicle controls were arbitrarily set to 1 in each case.    Bars and error 
bars indicate the means +/− SD for triplicate determinations in each case. **p < 0.01 vs. vehicle;  ***p < 0.001 vs. vehicle.
Figure 1: Basal MUC16 mRNA levels in various epithelial cell types. MUC16 mRNA levels were measured via quantitative 
qRT-PCR relative to the mRNA levels for ACTB in the indicated cell lines as described in Materials and Methods. IOSE 261F is the cell line 
with the lowest basal MUC16 mRNA levels and its value was arbitrarily set to 1 for comparison.  Although error bars are not evident in all 
cases, triplicate independent determinations were performed in each case with variation < 5% among samples.  In order to express all values 
on the same graph due to the very high basal levels of MUC16 expressed by OVCAR-3 cells a log base 10 scale was used for the Y-axis.
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achieved effective p65 knockdown (> 80%), no changes in 
MUC16 mRNA levels were noted (data not shown). Thus, 
the extremely high basal levels of MUC16 in this cell line 
appear to be due to processes independent of NFκB.
A conserved, consensus, NFκB binding site in the 
proximal MUC16 promoter accounts for much 
of the cytokine responsiveness
Knowing that the cytokine response was associated 
with the transcription factor NFκB, we next studied the 
MUC16 promoter to look for binding sites for NFκB and 
associated transcription factors. The start of transcription 
of the MUC16 gene has been predicted, but until now 
has not being biochemically determined. Therefore, we 
performed 5′ RACE to determine the start site of MUC16 
transcription. Two cell types were used for 5′ RACE, 
MCF-7 and OVCAR-3. It was found that MUC16 has 
alternative sites of transcription; it is cell type specific 
and differs by a few nucleotides from the predicted start 
site (Supplementary Figure 3). We next performed a 
bioinformatics analysis of the region 2000 bp upstream of 
the transcriptional start site to determine if any consensus 
NFκB binding sites occurred in this region and if they 
were conserved between mice and humans.  In the region 
within 200 bp from the start of transcription (Figure 8A) 
a consensus NFκB binding site was found in addition to 
others such as AP-1 and Sp1. To determine if the NFκB 
binding site was associated with the cytokine response, 
we cloned the proximal 250 bp of the MUC16 promoter 
into a pGL3 basic luciferase vector. Transient transfection 
reporter assays revealed that the 250 bp promoter accounts 
for a large portion of the cytokine responsiveness. 
Furthermore, mutating the NFκB binding site destroyed 
the cytokine response (Figure 8B and 8C). Thus, in 
addition to identifying NFκB as a key transcription 
factor mediating cytokine responsiveness of the MUC16 
gene, we also identified a key consensus NFκB binding 
element in the MUC16 promoter responsible for cytokine 
responsiveness.
Binding and recruitment of NFκB/p65 to the 
MUC16 promoter in vitro and in vivo
To determine if NFκB directly interacts with the 
consensus NFκB, both gel shift (EMSA) and chromatin 
immunoprecipitation (ChIP) assays were performed. 
Oligonucleotides either containing (EMSA) or flanking 
(ChIP) the putative NFκB binding site were designed 
for both assays, as well as an additional oligonucleotide 
containing a mutated NFκB for the EMSA assay as 
described in Material and Methods. As expected, the wild 
Figure 3: Cytokine treatments stimulate MUC16 mRNA levels in various cellular contexts. Each indicated cell line was 
treated for 48 h with either a vehicle control (0.1% [w/v] BSA in PBS), TNFα (2.5 ng/ml), IFNγ (20 IU), or a combination of TNFα + IFNγ. 
RNA then was extracted and the levels of MUC16 mRNA relative to that of ACTB was determined by qRT-PCR as described in Materials 
and Methods.  Values obtained for vehicle controls in each case were set to 1 for comparison.  The bars and error bars indicate the mean ± 
SD of triplicate independent determinations in each case.   ***p < 0.001, **p < 0.01 vehicle vs. IFNγ, TNFα or TNFα + IFNγ. Panels: (A) 
IOSE261F; (B) SKOv3-ip; (C) OVCAR-3; (D) RL95-2; (E) HEC50 and; (F) MCF-7.
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Figure 4: Time course of stimulation of MUC16 mRNA levels and protein production in response to combined cytokine 
treatment. MCF-7 cells were treated either with vehicle (0.1% [w/v] BSA in PBS) or TNFα (2.5 ng/ml) plus IFNγ (20 IU) for the indicated 
times. MUC16 mRNA levels were determined by qRT-PCR and amounts of cell-associated and secreted/shed MUC16 were determined 
by CA 125 ELISA assays as described in Materials and Methods. The bars and error bars indicate the mean ± SD of triplicate independent 
determinations in each case. Panels: (A) mRNA levels; (B) cell associated MUC16; (C) media MUC16.
Figure 5: Individual cytokines stimulate MUC16 protein production in MCF-7 cells. MCF-7 cells were treated for 6 days 
either with vehicle (0.1% [w/v] BSA in PBS), TNFα (2.5 ng/ml), IFNγ (20 IU), or TNFα + IFNγ. MUC16 levels then were determined 
(A) in the cell associated and media fractions by CA125 ELISA and (B) by immunofluorescence staining as described in Materials and 
Methods. Total MUC16 production was calculated by summing the amount of CA125 reactivity in the cell-associated and secreted fractions 
for each sample (A). A small stimulation of MUC16 production resulted from treatments with either TNFα or IFNγ alone. Much greater 
stimulation was observed with the combination of TNFα and IFNγ. The bars and error bars indicate the mean ± SD of triplicate independent 
determinations in each case. ***p < 0.001 vehicle vs. TNFα + IFNγ. (B) Vehicle; panels a, e and i; TNFα alone; panels b, f and j, IFNγ 
alone; panels c, g and k, or TNFα + IFNγ panels d, h and i. Cells were stained with MUC16 antibody (OC125; red) and DAPI (blue) and 
imaged.  Prior to immunostaining, cells were treated for six days with vehicle (0.1% [w/v] BSA in PBS; Figure 5B panels a, e and i), 
TNFα (2.5 ng/ml; Figure 5B panels b, f and j), IFNγ (20 IU; Figure 5B panels c, g and k), or TNFα + IFNγ (Figure 5B panels d, h and l). Cells 
subsequently were fixed and stained with MUC16 antibody (OC125; red) and DAPI (blue) and imaged.
Oncotarget7www.impactjournals.com/oncotarget
type oligonucleotide interacted with the recombinant NFκB/
p65 protein, while the mutated site showed very weak 
binding (Supplementary Figure 4A). ChIP experiments also 
showed an increased occupancy of the MUC16 promoters 
by NFκB following cytokine treatment when compared 
with the untreated control (Supplementary Figure 4B)
DISCUSSION
In the current study we demonstrated that the pro-
inflammatory cytokines TNFα and IFNγ stimulate MUC16 
expression in a variety of cellular contexts. Furthermore, 
we showed that elevated MUC16 expression is associated 
with elevated cytokine levels in several cancers of female 
reproductive tissues. We identified NFκB and a key NFκB 
binding site in the proximal MUC16 promoter as key 
mediators of this response. 
Stimulation of MUC16 expression by cytokines 
has been reported in ocular surface epithelial cell lines 
[24, 25]. In the present study we found that cytokines 
increase MUC16 mRNA and protein levels in a variety 
of epithelial cancer cell types. Knowing that cytokines 
stimulate expression of multiple transmembrane mucins 
suggests a general response potentially intended to 
enhance the protective functions of epithelia [20, 28]. In 
general, the degree to which cytokines stimulated MUC16 
expression was related to the basal level of MUC16 
expression, i.e. the lower the basal MUC16 level was the 
greater stimulation observed with cytokines.  We found 
that maximal MUC16 expression was observed with very 
low concentrations of cytokines used in combination. 
This suggests that in vivo low cytokine levels diffusing 
throughout a tumor may strongly potentiate MUC16 
expression.
While a large number of studies report serum 
cytokine levels or increases in cytokine mRNA levels in 
tumor tissues, very few have measured cytokine levels in 
tumor tissues [29].  These studies generally indicate that 
levels of TNFα and IFNγ are low in these tissues, but in 
the range where we observed cooperative stimulation of 
MUC16 expression.  It is likely that cytokine concentration 
gradients are created, radiating from the cellular sources 
of their production.  Nonetheless, the ability of these 
cytokines to cooperatively elevate MUC16 indicates that 
even low amounts of cytokines are sufficient to drive this 
response in tumors.  Moreover, these gradients may also 
account for heterogeneity in MUC16 expression within 
tumor tissues.
Figure 6: MUC16, TNFα, and IFNγ are co-expressed in malignant ovarian and uterine neoplasms.  Tissue staining and 
staining intensity assessments were performed as described in Materials and Methods.  A correlation between the intensity of MUC16 
staining and TNFα and IFNγ staining was observed in ovarian cancer (A) and to a lesser degree in breast cancer (B). Cytokine staining 
intensity was plotted against the staining intensity for MUC16 in each case and a correlation analysis was performed. Ovarian cancer TNFα 
vs MUC16: Correlation coefficient (r) = 0.8016.  r squared = 0.6426, The P value is 0.0006, considered extremely significant and IFNγ vs 
MUC16: Correlation coefficient (r) = 0.7077.  r squared = 0.5009, the P value is 0.0046, considered very significant. Breast cancer, TNFα 
vs MUC16: Correlation coefficient (r) = 0.4771.  r squared = 0.2276, the P value is 0.0389, considered significant and IFNγ vs MUC16: 
Correlation coefficient (r) = 0.7705.  r squared = 0.593, the P value is  0.0001, considered extremely significant. Data was plotted with a 
small variation to help visualization. Representative tissue microarray images show different combinations of MUC16, TNFα and IFNγ 
expression in different uterine neoplasms. (C) Representative staining of ovarian cancers scored as 1 or 3 for MUC16, TNFα and IFNγ 
with staining in both the cancer and stroma. Lower magnification, scale bars: 25 μm. Higher magnification (inset), scale bars: 10 μm. 
 (D) Representative staining of breast cancers scored as 1 or 3 for MUC16, TNFα and IFNγ. Lower magnification, scale bars: 25 μm. Higher 
magnification (inset), scale bars: 10 μm.
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Figure 7: MUC16 mRNA responsiveness to cytokines is attenuated when NFκB/p65 is knocked down by siRNA. MCF-7 
(A, C) and SKOv3-ip (B, D) cells were treated for 24 h with either scrambled or NFκB siRNA at a final concentration of 50 nM. Cells then 
were treated for 24 h with either a vehicle control (0.1% [w/v] BSA in PBS), or a combination of TNFα (2.5 ng/ml) plus IFNγ (20 IU). RNA 
then was extracted and the levels of NFκB/p65 (A and B) and MUC16 (C and D) mRNA relative to that of ACTB were determined by qRT-PCR 
as described in Materials and Methods. Values obtained for scrambled vehicle control in each case were set to 1 for comparison. The bars and 
error bars indicate the mean ± SD of triplicate independent determinations in each case. ***p < 0.001.
Figure 8: A consensus NFκB-binding site accounts for much of the MUC16 gene responsiveness to cytokines. 
(A) Diagram of the proximal 250 bp MUC16 promoter indicating the position of the putative NFκB binding site. +1 refers to the 5′RACE 
determined start of transcription for MCF-7 cells. (B) Sequence of the potential NFκB binding site and the mutated site generated for the 
transfection studies described in C. (C) MCF-7 cells were transfected with the wild type 250 bp proximal MUC16 reporter plasmid or the 
mutated putative NFκB binding site and then treated with either vehicle (0.1% [w/v] BSA in PBS), or TNFα (2.5 ng/ml) + IFNγ (20 IU) for 
24 h before measuring luciferase activity in cell lysates cells as described in Materials and Methods. Data are reported as the values obtained 
relative to the vehicle-treated wild type promoter.  The bars and error bars indicate the mean ± SD of triplicate independent determinations 
in each case. ***p < 0.001 wild type promoter vehicle vs. TNFα + IFNγ.
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Cytokine stimulation of mucin expression in cancer 
cells likely reflects conservation of a biological response 
of normal mucosal epithelia. Cytokines are elevated in 
normal tissues in response to injury or infection to prompt 
the immune system to respond to the challenge.  As part of 
this response, it appears that mucins are overproduced to 
protect the site from further damage or pathogenic invasion. 
In the case of cancer, these responses protect the mucin-
expressing cancer cells from the immune system [17, 30] 
and cytotoxic drug penetration [30, 31]. MUC16 can also 
carry ligands for immuno-inhibitory Siglecs [32, 33]. 
Thereby, the mucin response to cytokines represents a 
“vicious cycle”. Overexpression and shedding of MUC16 
is predicted to contribute to immunosuppressive activities 
further protecting tumor cells from host immune responses.
While many normal epithelial cells express MUC16 
[25, 34–36], it is not clear if shedding or cellular retention 
is the major metabolic fate. We found that ~66% of the 
MUC16 produced by MCF-7 cells is released to the 
medium.  The mechanism for this release is unclear at 
present, but may involve cell surface proteases as is the 
case for other transmembrane mucins [37, 38]. This is the 
first study describing the distribution of MUC16 between 
the cell-associated and shed/secreted compartments. 
More work detailing the mechanism of release as well as 
whether this occurs in other cell types is needed to know if 
this reflects a general behavior of MUC16 or is specialized 
to particular cell types.  In addition, determination of the 
biological functions of shed MUC16, beyond serving as a 
valuable serum marker, is needed. The energy expenditure 
in producing this huge glycoprotein (ca. 22,000 amino 
acids) heavily decorated with > 1 × 106 sugar residues is 
extraordinary.  An estimate of 2 nucleoside triphosphates 
(NTPs) used per amino acid addition and 36 ATPs 
potentially generated by complete oxidative metabolism 
of each hexose indicates an energetic cost of > 36 ×−106 
NTPs to produce one MUC16 molecule. Given this 
tremendous metabolic investment, it seems likely that the 
functions associated with MUC16 and its shed fragments 
are important.  Released MUC16 binds to the surfaces of 
various immune cells consistent with the aforementioned 
suggestion of an immunosuppressive function [11, 39]. 
Nonetheless, Muc16 null mice display no overt phenotypes 
[40]. It is possible that MUC16 functions in these mice are 
not manifest until presented with an appropriate challenge. 
MUC16 also binds the cell surface protein mesothelin on 
mesothelial cells, perhaps providing a way for migrating 
MUC16-expressing cells to colonize ectopic sites, e.g. the 
peritoneum. 
In this study we found that TNFα, IFNγ and MUC16 
are often strongly co-expressed in endometrial, breast 
and ovarian cancers with cytokine staining intensity 
positively correlating with MUC16 staining in breast and 
ovarian cancers, in particular.  These data are consistent 
with the notion that elevated cytokines in the tumor 
microenvironment induce the production of MUC16. We 
suggest that elevated MUC16, in turn, protects the tumor 
against the immune system and cytotoxic drug penetration. 
Our data provides important, novel information on 
cytokines as factors driving MUC16 expression in cancer 
cells and possibly in normal tissues as well. Regulation 
of MUC16 expression through NFκB could aid in early 
detection of ovarian cancer. CA125 (MUC16) levels can rise 
months to years prior to conventional diagnosis of ovarian 
cancer [41]. While administration of TNFα of IFNγ may or 
may not be tolerable clinically, selective enhancement of 
NFκB and MUC16 levels in cancer cells by other methods 
might provide a provocative test to confirm the presence 
of early stage ovarian cancer in asymptomatic women with 
rising levels of serum CA125 (MUC16). As MUC16 is 
likely important for metastasis in the peritoneal cavity [42], 
anti-inflammatory strategies might slow progression of the 
disease. Interfering with cytokine actions in tumor cells then 
represents an avenue to develop therapeutic approaches to 
reduce MUC16 levels to increase cancer cell susceptibility 
to the host immune system and cytotoxic drugs.
MATERIALS AND METHODS
Cell culture
Well-established cells with known genomic 
characterization were used. RL95-2 and HEC50, were 
cultured in DMEM/Hams F12 (Life Technologies; 11330–
057). IOSE 261F were cultured in MCDB 106 (SIGMA)/ 
MEDIUM 194 (MEDIATECH) [1:1, v/v]. SKOv3-
ip, were cultured in McCoy’s 5A (Thermo Scientific; 
SH30270.01). OVCAR-3, were cultured in RPMI 1640 
(Gibco®; 11875119). MCF-7 (last profiled on 7/22/13 by 
STR profiling at Johns Hopkins Genetic Resources Core 
Facility), were cultured in Minimum Essential Medium 
(MEM) (Life Technologies; 11095098).  All media were 
supplemented with 10% (v/v) fetal bovine serum (FBS) 
and penicillin (100 U/ml)–streptomycin (100 μg/ml) 
(Gibco®; 15140–122).  MCF-7 and OVCAR-3 cell media 
also were supplemented with 10 µg/ml of insulin (v/v) 
(Sigma-Aldrich Inc.; I9278).
Cytokine treatments
Cells were seeded in six well plates in media containing 
5% (v/v) charcoal-stripped FBS (Life Technologies; 
12676029) and allowed to reach 60–70% confluence. Cells 
then were gently rinsed with PBS and then serum free 
medium was added for 24 h.  Cells then were treated with 
tumor necrosis factor alpha (TNFα, ROCHE; 113718430) 
and or interferon gamma (IFNγ ROCHE; 11040596001) at 
the concentrations indicated in the text in media containing 
10% (v/v) charcoal-stripped FBS. Cells were incubated with 
cytokines for 48 h prior to RNA extraction and for six days 
prior to protein extraction and immunostaining, and for up to 
12 days in time course experiments.
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RNA isolation and reverse transcription-PCR. 
Total RNA was isolated by using TRIZOL reagent 
(Invitrogen; 15596–026) and chloroform (Cambridge 
Isotope Laboratories; DLM-7TB-100). Samples then 
were treated with DNAse according to the manufacturer’s 
instructions (Ambion; AM1906). Reverse transcription 
was performed using 1 µg of total RNA in a 10 µl 
reaction using qScript cDNA Super mix (Quanta; 95048) 
incubated for 5 min at 25°C, 30 min at 42°C and 5 min 
at 85°C. Real time qPCR was performed using the 
following primer sequences: MUC16 forward, 5′- GCC 
TCTACCTTAACGGTTACAATGAA-3′and reverse, 5′- G 
GTACCCCATGGCTGTTGTG-3′ [25] beta actin (ACTB) 
forward, 5′-GATGAGATTGGCATGGCTTT-3′and reverse, 
5′- CACCTTCACCGGTCCAGTTT-3′ [43] and NFкβ 
forward, 5′- ATCTGCCGAGTGAACCGAAACT-3′ and 
reverse, 5′- CCAGCCTGGTCCCGTGAAA -3′ [44] and 
SYBR Green Super mix according to the manufacturer’s 
instructions (Quanta Bioscience). Samples were cycled as 
follows: MUC16, (30 sec at 95°C and 30 sec at 59°C for 
40 cycles); NFкB p65 (an initial incubation at 50°C for 
2 min followed by 40 cycles of 95°C for 10 min, 95°C 
for 15 s and 60°C for 1 min [44]). Relative amounts of 
mRNA were identified using the comparative threshold 
cycle method [45, 46] and normalized to that of ACTB.
Immunofluorescence analysis
Cells (5 × 104) were plated in 8-well chamber slides 
and treated with cytokines for six days. Cells were washed 
with PBS and fixed with 100% methanol for 10 min at 
room temperature. Subsequently, cells were washed and 
allowed to re-hydrate for 10 min at room temperature in 
PBS. Slides were washed three times with PBS, blocked for 
1 h with [3% (w/v) BSA in PBS] and washed three times 
with PBS. Primary antibody was added and incubated 
overnight at room temperature at the indicated dilutions: 
mouse monoclonal anti-MUC16 (OC125); 1:100 in 
blocking solution. Slides were washed three times with 
PBS, then incubated with 1:400 dilution of Alexa-fluor 647 
goat anti-mouse (Invitrogen; A21235) in blocking solution 
at room temperature for 1 h in the dark, and washed three 
times for 5 min at room temperature with PBS. Samples 
were mounted with Prolong-Antifade with 4′, 6-diamidino-
2-phenylindole (DAPI), a fluorescent molecule that binds 
strongly to A-T regions in DNA in the nucleus, as per 
manufacturer’s instructions (Life Technologies; P-36931) 
and viewed by confocal microscopy on a Zeiss LSM710 
microscope.
ELISAs
Cells were plated (4 × 105) in six-well plates and 
treated with cytokines for six or up to 12 days. Fresh 
media with cytokines was changed every three days and 
conditioned media was saved. Protein from cell lysates 
was isolated using 500 µl of RIPA lysis buffer (Santa 
Cruz; sc-24948). ELISA assays were performed using 
CA125 ELISA kit (BQ kits; BQ1013T) following the 
manufacturer’s instructions.
siRNA knockdown
NFκB was knocked down using an oligonucleotide 
targeting p65 (Santa Cruz; sc-29410/human NFκB 
p65 siRNA) and a non-silencing, scrambled siRNA 
control: (5′- AATTCTCCGAACGTGTCACGT-3′ [47]. 
All siRNAs were resuspended in RNAse-free water 
to a final concentration of 10 μM by adding 330 µl 
of RNase-free water to 3.3 nmol of lyophilized siRNA 
for NFκB p65 and by adding 1 mL of RNAse-free water 
to the lyophilized siRNA to achieve a final concentration 
of 20 μM for the scrambled control. Oligonucleotides 
were transfected using Lipofectamine 2000 (Invitrogen; 
11668019) according to the manufacturer’s instructions. 
Briefly, cells were plated in antibiotic free media in 
12 well plates incubated for 24 h at 37° in a humidified 
atmosphere of air: CO2 (95:5, v/v). Oligonucleotides 
were transfected at a final concentration of 50 nM in 
Opti-MEM® Reduced Serum Medium, GlutaMAX™ 
Supplement (Gibco; 51985034).  Six h after transfection, 
media was changed to regular medium plus FBS lacking 
antibiotics. Twenty four h later cells were treated with or 
without cytokines for 24 h followed by RNA extraction.
Immunohistochemistry
 Formalin-fixed, paraffin-embedded tumors were 
resected from 94 patients and obtained from the archives 
of Department of Pathology, MD Anderson Cancer Center 
(Houston, TX). The MDACC Institutional Review Board 
approved the use of tissue. To provide a positive control, 
SKOv3-ip cells were grown for 24 h in McCoy’s medium 
supplemented with 10% (v/v) FBS, 1% (penicillin [100 U/
ml]–streptomycin [100 μg/ml], and 1% [w/v] L-glutamine. 
Cells were harvested in 0.25% (w/v) trypsin (Fisher 
Scientific, MT-25-052-CI) washed 2 times in PBS, fixed 
in 10% (w/v) formalin and embedded in paraffin.  Oven 
incubation at 60°C for 20 min was used to deparaffinize 
slides followed by two 20 min incubations at room 
temperature in xylene.  After slides were rehydrated, 
antigen retrieval was performed in 6.5 mM sodium citrate 
buffer (pH 6.0) for 10 min. Blocking was performed with 
5% (w/v) bovine serum albumin in PBS. The primary 
antibody (anti-TNFα mouse monoclonal, 1:200, EDM 
Millipore MAB1096; anti-IFNγ rabbit polyclonal, 1:250, 
Novus Biologicals NBP1-19761; or OC125 mouse 
monoclonal 1:400, R.C. Bast Laboratory) were incubated 
at 4°C overnight. Mouse or rabbit secondary antibody 
(Jackson ImmunoResearch) was applied for 1 h at room 
temperature followed by washing 3 times in PBS for 
10 min.  Diaminobenzidene chromagen (Biocare Medical, 
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BDB 2004L) was added for 1 min per slide followed by 3 
additional washes in PBS for 10 min and then hematoxylin 
staining was performed for 1 min per slide followed by 
3 additional washes in PBS for 10 min. Serial sections 
of paraffin-embeded OVCAR-3 cells and non-immune 
IgG staining served as positive and negative controls, 
respectively, and were stained alongside tissue microarray 
(TMAs) to confirm assay reproducibility.  Omission of the 
primary antibody served as an additional negative control 
for each immunostaining event. Immunohistochemical 
staining was evaluated for both overall staining intensity and 
location of the staining in the tumor or stroma alone versus 
diffuse staining in both tissues.  Total staining intensity 
was determined as 0 (no staining), 1 (weak staining), 2 
(moderate staining), and 3 (strong staining). All slides were 
evaluated independently by 2 investigators (ZL and MNS) 
without knowledge of the identity of the patient or clinical 
outcome.
5′ Rapid amplification of cDNA ends 
(RACE)
RACE PCR was performed to formally determine 
the MUC16 transcriptional start site.  These reactions were 
performed using the 5′RACE System (Life Technologies; 
18374–058) according to the manufacturer’s instructions. 
Primers used were, GSP1: 5′- CACCACGAT 
TGCACCTGTAG -3′ and GSP2 5′- TTAGTGCTCCTGC 
TCCCTGT -3′. The PCR products then were sequenced 
using the GSP3 primer 5′- CCAGAGGCAA ATGTTGACC 
T -3′.
MUC16 promoter plasmid construction
 Genomic DNA was purified from MCF-7 cells 
using a Wizard® SV Genomic DNA Purification System 
(Promega: A2360). A construct containing 250 bp upstream 
of the start site of MUC16 transcription (hereafter refer to 
as 250 bp promoter construct) was amplified by genomic 
PCR. This PCR product was cloned into pCR 2.1 TOPO 
(Life Technologies; K456001). This fragment was ligated 
into the promoter less pGL3 firefly luciferase reporter 
vector (Promega; E1751). The primers used were Fwd: 
5′- AGAGAGAGAGAGAGAGAGGATCATT -3′ Rev 5′- 
AATGATCCTCTCTCTCTCTCTCTCT -3′. Site directed 
mutagenesis was performed using the QuikChange 
Lightning Site-Directed Mutagenesis Kit (Agilent 
Technologies Inc; 210518) according to the manufacturer’s 
instructions. 
Transient transfection and reporter assays
 MCF-7 or SKOv3-ip cells were plated in 5% (v/v) 
charcoal-stripped FBS in six-well plates and maintained 
for 48 h until the cells reached 80 to 90% confluence 
judged by eye. Transient transfections were performed 
using Lipofectamine 2000 (Invitrogen; 11668–019) and 
Opti-MEM (Life Technologies; 51985034) according 
to the manufacturer’s instruction. Expression and 
reporter plasmids were added at 500 ng and 1 μg per 
well, respectively, and 10 ng of pRL-TK plasmid was 
used per well. After transfection cells were allowed to 
recover in serum free media for 12 h. Cytokine treatments 
were added as described above for 24 h. The Dual-
Luciferase Assay kit (Promega; E1960) was used to lyse 
the cells and perform the luciferase assay according to 
the manufacturer’s instructions. Reporter activity was 
expressed as the ratio of firefly luciferase activity to 
Renilla luciferase activity.
Electrophoretic mobility shift assay (EMSA)
Recombinant NFκB p65 protein (Active 
Motif; 31102)(500 ng) was incubated with 40 ng of 
oligonucleotide probes for NFκB p65 containing either 
a consensus (5′- CGACATGATACACTA AGAAATTC 
TATTCTGCAGACACTGC -3′) or a mutated (5′- CGAC 
ATGATACACTAAGAAAAAATATTCTGCAGACACTG 
C -3′) sequence, similar to the NFκB sequence found in 
the MUC16 promoter by bioinformatics analysis and used 
in the luciferase assay, in a reaction mixture following the 
manufacturers instructions containing 2 μl of EMSA/Gel-
shift binding buffer 5× from EMSA Kit (ThermoFisher; 
E33075) containing 750 mM KCl, 0.5 mM dithiothreitol, 
0.5 mM EDTA, 50 mM Tris, pH 7.4 for 40 min. The 
reaction mixtures were separated by 12% non-denaturing 
PAGE. The gel was then stained for 20 min with 1× 
SYBR® green staining solution; the gel was then washed 
with dH20 two times for ~2 sec followed by visualization 
using a Carestream Imaging system. 
Chromatin immunoprecipitation (ChIP)
The Chromatrap® kit (Porvair Sciences – 
Leatherhead, Surrey, England) was used for ChIP assays. 
MCF-7 cells were grown to 60 to 80% confluency and 
serum-withdrawn overnight, then treated for 4 h with 
TNF-α (2.5 ng/mL) and IFNγ (20 IU) or vehicle control 
prior to collection of chromatin. Fixation, DNA shearing 
and ChIP were performed following the manufacturer’s 
instructions. Antibodies included the anti-p65 SC-109X 
antibody (Santa-Cruz), as well as a control IgG antibody. 
Primer sequences used to amplify NFκB regulatory region 
are 1) Fwd: 5′-AGCCTGGTTCCTGGTTTCTAA -3′ and 
Rev: 5′-CCCTTCAAACTTTTTAACGGATT -3′ and 2) 
5′-GCCTGGTTCCTGGTTTCTAA-3′.
Rev: 5′-TGATCTCAATTCTTCCCTTCAAA-3′. 
The NFKBIA gene promoter served as a positive control 
for p65 immunoprecipitation, and the GAPDH promoter 
was used a positive control for RNA polymerase II 
immunoprecipitation. The HBB gene was the negative 
control for nonspecific pulldown by either the antibody or 
adsorption by the column beads.
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Statistical analysis
All data is shown as the mean ± SD of triplicate 
determinations of independent biological samples. 
Statistical analyses were performed using a one-way 
ANOVA followed by Tukeys post-test using GraphPad 
InStat software, version 3.05 (GraphPad Software, San 
Diego, CA). Differences were considered significant when 
P < 0.05, two-tailed test.
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